The 86th ADA Scientific Sessions wrapped Monday June 8 after presenting Phase 3 retatrutide TRIUMPH-1/TRANSCEND-T2D-1, CagriSema REIMAGINE 1/2/3, Foundayo ACHIEVE 1-5, survodutide SYNCHRONIZE-1, petrelintide ZUPREME-1, enicepatide CT388-103, elecoglipron VISTA/SOLSTICE, mazdutide GLORY-2/DREAMS-3, zenagamtide Phase 2, plus the inaugural ADA Standards of Care in Overweight and Obesity. The next inflection points: the July 23-24 PCAC peptide-compounding meeting, August 28 ITM-11 PDUFA in NETs, and the Foundayo T2D filing in Q2.
The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.
The American Diabetes Association's late-breaking abstracts release Friday, June 5 at 6:30 p.m. Central, opening the meeting's data flood in New Orleans (June 5-8). Queued readouts include MetaVia's dual oxyntomodulin DA-1726 and GPR119 agonist vanoglipel, Structure's oral aleniglipron, and Hengrui and Kailera's oral incretins, alongside the Phase 3 retatrutide symposium June 6 and the orforglipron symposium June 8. Novo Nordisk holds an R&D investor event June 7.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
The American Diabetes Association's 86th Scientific Sessions open June 5-8 with the year's deepest metabolic-peptide slate. Lilly presents full TRIUMPH-1 obesity data and the first retatrutide diabetes Phase 3, TRANSCEND-T2D-1, plus the orforglipron ACHIEVE program comparing the oral GLP-1 against dapagliflozin, oral semaglutide, and placebo. Innovent's mazdutide brings GLORY-2 and the DREAMS-3 head-to-head versus semaglutide, AstraZeneca's eleglipron carries full Phase 2b data, and Lilly's GLP-1/GIP/glucagon/amylin/calcitonin quintuple agonist takes a plenary slot.
The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.